Free Trial
TSE:ATE

Antibe Therapeutics (ATE) Stock Price, News & Analysis

C$0.30
0.00 (0.00%)
(As of 05/24/2024)
Today's Range
C$0.30
C$0.30
50-Day Range
C$0.17
C$0.45
52-Week Range
C$0.15
C$1.23
Volume
N/A
Average Volume
135,475 shs
Market Capitalization
C$15.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ATE stock logo

About Antibe Therapeutics Stock (TSE:ATE)

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

ATE Stock Price History

ATE Stock News Headlines

Antibe Extends Early Warrant Exercise Incentive Program
Antibe Therapeutics Inc ATE
Antibe Announces Early Warrant Exercise Incentive Program
Hercules at 52-Week High on Barrick Hookup
Antibe at 52-Week High on News
Stocks in play: Antibe Therapeutics Inc.
Antibe Therapeutics Inc. (ATE)
Last Week of June Looks Eventful
Best Times To Visit Antibes
See More Headlines
Receive ATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/28/2024
Next Earnings (Estimated)
7/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Net Income
C$-18,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$9.71 million
Cash Flow
C$0.48 per share
Book Value
C$0.49 per share

Miscellaneous

Free Float
N/A
Market Cap
C$15.64 million
Optionable
Not Optionable
Beta
0.19
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Daniel Marcel Legault J.D. (Age 66)
    L.L.B., President, CEO, Secretary & Director
    Comp: $744.67k
  • Mr. Alain Wilson M.B.A.
    MBA, Chief Financial Officer
  • Mr. Scott Curtis C.F.A.
    M.Eng, Chief Operating Officer
  • Dr. David James Vaughan Ph.D. (Age 74)
    Chief Development Officer
    Comp: $406.58k
  • Dr. Joseph Stauffer D.O. (Age 58)
    M.B.A., Chief Medical Officer
    Comp: $1.11M
  • Dr. Ana Stegic
    Executive Director of Clinical Operations
  • Ms. Christina Cameron B.B.A.
    Vice President of Investor Relations
  • Mr. Philip Stern
    Vice President of Communications

ATE Stock Analysis - Frequently Asked Questions

Should I buy or sell Antibe Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATE, but not buy additional shares or sell existing shares.
View ATE analyst ratings
or view top-rated stocks.

How have ATE shares performed in 2024?

Antibe Therapeutics' stock was trading at C$0.93 on January 1st, 2024. Since then, ATE shares have decreased by 68.3% and is now trading at C$0.30.
View the best growth stocks for 2024 here
.

When is Antibe Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024.
View our ATE earnings forecast
.

Is Antibe Therapeutics a good dividend stock?

Antibe Therapeutics (TSE:ATE) pays an annual dividend of C$0.05 per share and currently has a dividend yield of 0.00%.

How do I buy shares of Antibe Therapeutics?

Shares of ATE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:ATE) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners